BioLargo, Inc. (BLGO) stock
BLGOOTCChemicals & Allied ProductsFiscal year ends December 31
$0.07+0.00 (+0.90%)
Close on Oct 19, 2026Market cap $23.27MP/E –Yield –
BioLargo r&d expenses
Research and development expenses are spending on new products and technology.
BioLargo's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.27M, up 16.8% year over year. For fiscal 2025 it was $2.59M, down 10.0% from the year before. Over ten years it grew 14.2% a year on average. The highest annual figure on record is $2.88M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.59M | -10.0% |
| FY2024 | Dec 31, 2024 | $2.88M | +26.3% |
| FY2023 | Dec 31, 2023 | $2.28M | +73.0% |
| FY2022 | Dec 31, 2022 | $1.32M | -3.5% |
| FY2021 | Dec 31, 2021 | $1.37M | +2.2% |
| FY2020 | Dec 31, 2020 | $1.34M | -9.1% |
| FY2019 | Dec 31, 2019 | $1.47M | -14.4% |
| FY2018 | Dec 31, 2018 | $1.72M | +5.5% |
| FY2017 | Dec 31, 2017 | $1.63M | +17.9% |
| FY2016 | Dec 31, 2016 | $1.38M | +101.9% |
| FY2015 | Dec 31, 2015 | $684.55K | +6.5% |
| FY2014 | Dec 31, 2014 | $642.92K | -13.4% |
| FY2013 | Dec 31, 2013 | $742.25K | +93.5% |
| FY2012 | Dec 31, 2012 | $383.55K | +285.5% |
| FY2011 | Dec 31, 2011 | $99.50K | -1.1% |
| FY2010 | Dec 31, 2010 | $100.56K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.09M | +103.4% |
| Q1 FY2026 | Mar 31, 2026 | $907.00K | +14.7% |
| Q4 FY2025 | Dec 31, 2025 | $659.00K | -15.9% |
| Q3 FY2025 | Sep 30, 2025 | $615.00K | -10.9% |
| Q2 FY2025 | Jun 30, 2025 | $535.00K | -14.1% |
| Q1 FY2025 | Mar 31, 2025 | $791.00K | +0.9% |
| Q4 FY2024 | Dec 31, 2024 | $784.00K | +79.8% |
| Q3 FY2024 | Sep 30, 2024 | $690.00K | -0.6% |
| Q2 FY2024 | Jun 30, 2024 | $623.00K | +6.1% |
| Q1 FY2024 | Mar 31, 2024 | $784.00K | +38.8% |
| Q4 FY2023 | Dec 31, 2023 | $436.00K | +44.9% |
| Q3 FY2023 | Sep 30, 2023 | $694.00K | +156.1% |
| Q2 FY2023 | Jun 30, 2023 | $587.00K | +65.4% |
| Q1 FY2023 | Mar 31, 2023 | $565.00K | +44.1% |
| Q4 FY2022 | Dec 31, 2022 | $301.00K | -11.5% |
| Q3 FY2022 | Sep 30, 2022 | $271.00K | -21.2% |
| Q2 FY2022 | Jun 30, 2022 | $355.00K | -0.3% |
| Q1 FY2022 | Mar 31, 2022 | $392.00K | +19.9% |
| Q4 FY2021 | Dec 31, 2021 | $340.00K | +10.7% |
| Q3 FY2021 | Sep 30, 2021 | $344.00K | -0.9% |
| Q2 FY2021 | Jun 30, 2021 | $356.00K | +1.7% |
| Q1 FY2021 | Mar 31, 2021 | $327.00K | -2.4% |
| Q4 FY2020 | Dec 31, 2020 | $307.00K | -11.3% |
| Q3 FY2020 | Sep 30, 2020 | $347.00K | +4.5% |
| Q2 FY2020 | Jun 30, 2020 | $350.00K | -4.6% |
| Q1 FY2020 | Mar 31, 2020 | $335.00K | -21.4% |
| Q4 FY2019 | Dec 31, 2019 | $346.00K | +5.5% |
| Q3 FY2019 | Sep 30, 2019 | $332.00K | -24.9% |
| Q2 FY2019 | Jun 30, 2019 | $367.00K | -13.6% |
| Q1 FY2019 | Mar 31, 2019 | $426.00K | -18.4% |
| Q4 FY2018 | Dec 31, 2018 | $328.00K | -32.9% |
| Q3 FY2018 | Sep 30, 2018 | $442.00K | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $425.00K | +31.1% |
| Q1 FY2018 | Mar 31, 2018 | $522.00K | +33.4% |
| Q4 FY2017 | Dec 31, 2017 | $488.71K | +38.7% |
| Q3 FY2017 | Sep 30, 2017 | $425.67K | +22.1% |
| Q2 FY2017 | Jun 30, 2017 | $324.28K | – |
| Q1 FY2017 | Mar 31, 2017 | $391.34K | – |
| Q4 FY2016 | Dec 31, 2016 | $352.32K | – |
| Q3 FY2016 | Sep 30, 2016 | $348.62K | – |
See a number that looks wrong?